Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: Report of three cases
Articolo
Data di Pubblicazione:
2005
Citazione:
Rituximab as treatment of posttransplant lymphoproliferative disorder in patients who underwent small bowel/multivisceral transplantation: Report of three cases / M., C., S., C., Guaraldi, G., Di Benedetto, F., A., B., M., P., W., G., A. D., P., Gerunda, G.E., Esposito, R.. - In: TRANSPLANTATION PROCEEDINGS. - ISSN 0041-1345. - STAMPA. - 37:6(2005), pp. 2634-2635. [10.1016/j.transproceed.2005.06.032]
Abstract:
This report describes three cases of posttransplant lymphoproliferative disorder (PTLD) in multivisceral/small bowel transplant patients treated with rituximab (anti-CD20 monoclonal antibodies). In two cases (one of which was a B-cell lymphoma) a good response to therapy was achieved. A third case (with polymorphic PTLD with low CD20 expression) developed a refractory rejection and PTLD was still documented on graftectomy. Rituximab was well tolerated, and a reduction of Epstein-Barr virus (EBV) viral load was documented by quantitive competitive-EBV polymerase chain reaction. Efficacy of therapy needs to be assessed in controlled studies.
Tipologia CRIS:
Articolo su rivista
Keywords:
Adolescent, Adult, Antibodies; Monoclonal, Biopsy, Bone Marrow, Fatal Outcome, Female, Gardner Syndrome, Humans, Intestine; Small, Lymphoproliferative Disorders, Male, Postoperative Complications, Treatment Outcome, Viscera
Elenco autori:
M., Codeluppi; S., Cocchi; Guaraldi, Giovanni; Di Benedetto, Fabrizio; A., Bagni; M., Pecorari; W., Gennari; A. D., Pinna; Gerunda, Giorgio Enrico; Esposito, Roberto
Link alla scheda completa:
Pubblicato in: